CNSY
Cerenome Inc.
CNSY | NASDAQ
$1.75
+$0.05 (+3.24%)
Nov 2, 2026, 10:59 AM ET · Market open
Company Profile
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.
Key Executives
| Name | Position |
|---|---|
| Marc H. Hedrick | President, CEO & Director |
| Andrew J. Sims | VP & CFO |
| Desiree Smith | Corporate Controller |
| Eric J. Daniels | Chief Development Officer |
| Russ Havranek | Executive Vice President of Commercial and Corporate Strategy |
| Russell W. Bradley | President & GM of CNSide Diagnostics, LLC |
Cerenome Inc.
CNSY
| Country | United States |
| IPO Date | Aug 3, 2026 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Marc H. Hedrick |
Contact Details
6420 Levit Green Blvd Houston,
Texas 77021 United States
Stock Details
| Ticker Symbol | CNSY |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | 72941H806 |
| ISIN Number | US72941H8060 |
| SIC Code | n/a |
Add to Watchlist
Select watchlists to add or remove CNSY